Uncategorized
Phase 2a begins for emixustat for macular atrophy, Stargardt’s
Acucela Inc. announced that the first patient has been enrolled in a study to evaluate its leading drug candidate, emixustat HCl, in subjects with macular atrophy secondary to Stargardt’s disease, according to a press release.The multicenter, randomized, masked phase 2a study is designed to evaluate the pharmacodynamics, safety and tolerability of emixustat in subjects with macular atrophy secondary to Stargardt’s disease. About 30 subjects will be enrolled at four to six clinical sites across the U.S. Subjects will be randomly assigned to one of three treatment arms in a 1:1:1 (Read more...)